{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:15:49Z","timestamp":1791288949454,"version":"4.3.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1038\/nbt1342","type":"journal-article","created":{"date-parts":[[2007,11,7]],"date-time":"2007-11-07T20:25:24Z","timestamp":1194467124000},"page":"1265-1275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":420,"title":["Complement-targeted therapeutics"],"prefix":"10.1038","volume":"25","author":[{"given":"Daniel","family":"Ricklin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Lambris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,11,7]]},"reference":[{"key":"BFnbt1342_CR1","first-page":"353","volume":"4","author":"G Nuttall","year":"1888","unstructured":"Nuttall, G. Experimente \u00fcber die bacterienfeindlichen Einfl\u00fcsse des thierischen K\u00f6rpers. Z. Hyg. Infektionskr. 4, 353\u2013394 (1888).","journal-title":"Z. Hyg. Infektionskr."},{"key":"BFnbt1342_CR2","unstructured":"Ehrlich, P. & Morgenroth, J. Ueber haemolysine\u2014zweite mittheilung. Berl. Klin. Wochenschr., 481\u2013486 (1899)."},{"key":"BFnbt1342_CR3","unstructured":"US Food and Drug Administration. FDA approves first-of-its-kind drug to treat rare blood disorder (USFDA, Rockville, MD, USA) (http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2007\/NEW01589.html) (March 16, 2007)."},{"key":"BFnbt1342_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0167-5699(98)01341-3","volume":"19","author":"JO Sunyer","year":"1998","unstructured":"Sunyer, J.O., Zarkadis, I.K. & Lambris, J.D. Complement diversity: a mechanism for generating immune diversity? Immunol. Today 19, 519\u2013523 (1998).","journal-title":"Immunol. Today"},{"key":"BFnbt1342_CR5","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport, M.J. Complement. First of two parts. N. Engl. J. Med. 344, 1058\u20131066 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt1342_CR6","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport, M.J. Complement. Second of two parts. N. Engl. J. Med. 344, 1140\u20131144 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt1342_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.it.2005.12.008","volume":"27","author":"MP Longhi","year":"2006","unstructured":"Longhi, M.P., Harris, C.L., Morgan, B.P. & Gallimore, A. Holding T cells in check\u2013a new role for complement regulators? Trends Immunol. 27, 102\u2013108 (2006).","journal-title":"Trends Immunol."},{"key":"BFnbt1342_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.imlet.2004.11.010","volume":"97","author":"BP Morgan","year":"2005","unstructured":"Morgan, B.P., Marchbank, K.J., Longhi, M.P., Harris, C.L. & Gallimore, A.M. Complement: central to innate immunity and bridging to adaptive responses. Immunol. Lett. 97, 171\u2013179 (2005).","journal-title":"Immunol. Lett."},{"key":"BFnbt1342_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S1471-4906(02)02287-1","volume":"23","author":"D Mastellos","year":"2002","unstructured":"Mastellos, D. & Lambris, J.D. Complement: more than a 'guard' against invading pathogens? Trends Immunol. 23, 485\u2013491 (2002).","journal-title":"Trends Immunol."},{"key":"BFnbt1342_CR10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1172\/JCI28622","volume":"116","author":"JP Atkinson","year":"2006","unstructured":"Atkinson, J.P. & Frank, M.M. Bypassing complement: evolutionary lessons and future implications. J. Clin. Invest. 116, 1215\u20131218 (2006).","journal-title":"J. Clin. Invest."},{"key":"BFnbt1342_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.it.2007.02.006","volume":"28","author":"MM Markiewski","year":"2007","unstructured":"Markiewski, M.M., Nilsson, B., Nilsson Ekdahl, K., Mollnes, T.E. & Lambris, J.D. Complement and coagulation: strangers or partners in crime? Trends Immunol. 28, 184\u2013192 (2007).","journal-title":"Trends Immunol."},{"key":"BFnbt1342_CR12","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1074\/jbc.M508928200","volume":"281","author":"DE Hourcade","year":"2006","unstructured":"Hourcade, D.E. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J. Biol. Chem. 281, 2128\u20132132 (2006).","journal-title":"J. Biol. Chem."},{"key":"BFnbt1342_CR13","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.4049\/jimmunol.179.4.2600","volume":"179","author":"D Spitzer","year":"2007","unstructured":"Spitzer, D., Mitchell, L.M., Atkinson, J.P. & Hourcade, D.E. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 179, 2600\u20132608 (2007).","journal-title":"J. Immunol."},{"key":"BFnbt1342_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1034\/j.1600-065X.2001.1800113.x","volume":"180","author":"MD Kirkitadze","year":"2001","unstructured":"Kirkitadze, M.D. & Barlow, P.N. Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol. Rev. 180, 146\u2013161 (2001).","journal-title":"Immunol. Rev."},{"key":"BFnbt1342_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1201\/9780849350368-2","volume-title":"Structural Biology of the Complement System","author":"DC Soares","year":"2005","unstructured":"Soares, D.C. & Barlow, P.N. Complement control protein modules in the regulators of complement activation. in Structural Biology of the Complement System. (eds. Morikis, D. & Lambris, J.D.) 19\u201362 (CRC Press, Boca Raton, Florida, 2005)."},{"key":"BFnbt1342_CR16","doi-asserted-by":"publisher","DOI":"10.1201\/b14212","volume-title":"The Human Complement System in Health and Disease","author":"JE Volanakis","year":"1998","unstructured":"Volanakis, J.E. & Frank, M. (eds.). The Human Complement System in Health and Disease. (Marcel Dekker, Inc., New York, 1998)."},{"key":"BFnbt1342_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0162-3109(00)80299-4","volume":"49","author":"A Sahu","year":"2000","unstructured":"Sahu, A. & Lambris, J.D. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 49, 133\u2013148 (2000).","journal-title":"Immunopharmacology"},{"key":"BFnbt1342_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2353\/ajpath.2007.070166","volume":"171","author":"MM Markiewski","year":"2007","unstructured":"Markiewski, M.M. & Lambris, J.D. The role of complement in inflammatory diseases\u2014from behind the scenes into the spotlight. Am. J. Pathol. 171, 715\u2013727 (2007).","journal-title":"Am. J. Pathol."},{"key":"BFnbt1342_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev.immunol.22.012703.104549","volume":"22","author":"AP Manderson","year":"2004","unstructured":"Manderson, A.P., Botto, M. & Walport, M.J. The role of complement in the development of systemic lupus erythematosus. Annu. Rev. Immunol. 22, 431\u2013456 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnbt1342_CR20","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1146\/annurev.immunol.23.021704.115835","volume":"23","author":"RF Guo","year":"2005","unstructured":"Guo, R.F. & Ward, P.A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23, 821\u2013852 (2005).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnbt1342_CR21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.molimm.2006.03.007","volume":"44","author":"DM Bonifati","year":"2007","unstructured":"Bonifati, D.M. & Kishore, U. Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol. 44, 999\u20131010 (2007).","journal-title":"Mol. Immunol."},{"key":"BFnbt1342_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.molimm.2005.06.015","volume":"43","author":"PF Zipfel","year":"2006","unstructured":"Zipfel, P.F., Heinen, S., Jozsi, M. & Skerka, C. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol. Immunol. 43, 97\u2013106 (2006).","journal-title":"Mol. Immunol."},{"key":"BFnbt1342_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clim.2004.05.007","volume":"114","author":"AE Davis III.","year":"2005","unstructured":"Davis, A.E. III., The pathophysiology of hereditary angioedema. Clin. Immunol. 114, 3\u20139 (2005).","journal-title":"Clin. Immunol."},{"key":"BFnbt1342_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.iac.2006.08.004","volume":"26","author":"IG Wagenaar-Bos","year":"2006","unstructured":"Wagenaar-Bos, I.G. & Hack, C.E. Structure and function of C1-inhibitor. Immunol. Allergy Clin. North Am. 26, 615\u2013632 (2006).","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"BFnbt1342_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06554.x","volume":"137","author":"A Hill","year":"2007","unstructured":"Hill, A., Richards, S.J. & Hillmen, P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 137, 181\u2013192 (2007).","journal-title":"Br. J. Haematol."},{"key":"BFnbt1342_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molimm.2006.06.011","volume":"44","author":"SH Rooijakkers","year":"2007","unstructured":"Rooijakkers, S.H. & van Strijp, J.A. Bacterial complement evasion. Mol. Immunol. 44, 23\u201332 (2007).","journal-title":"Mol. Immunol."},{"key":"BFnbt1342_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.biopha.2006.07.087","volume":"60","author":"PK Datta","year":"2006","unstructured":"Datta, P.K. & Rappaport, J. HIV and complement: hijacking an immune defense. Biomed. Pharmacother. 60, 561\u2013568 (2006).","journal-title":"Biomed. Pharmacother."},{"key":"BFnbt1342_CR28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/ni1450","volume":"8","author":"M Hammel","year":"2007","unstructured":"Hammel, M. et al. A structural basis for complement inhibition by Staphylococcus aureus. Nat. Immunol. 8, 430\u2013437 (2007).","journal-title":"Nat. Immunol."},{"key":"BFnbt1342_CR29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1084\/jem.20031636","volume":"199","author":"CJ de Haas","year":"2004","unstructured":"de Haas, C.J. et al. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J. Exp. Med. 199, 687\u2013695 (2004).","journal-title":"J. Exp. Med."},{"key":"BFnbt1342_CR30","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/ni1235","volume":"6","author":"SH Rooijakkers","year":"2005","unstructured":"Rooijakkers, S.H. et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 6, 920\u2013927 (2005).","journal-title":"Nat. Immunol."},{"key":"BFnbt1342_CR31","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S1359-6446(05)03592-0","volume":"10","author":"S Bureeva","year":"2005","unstructured":"Bureeva, S., Andia-Pravdivy, J. & Kaplun, A. Drug design using the example of the complement system inhibitors' development. Drug Discov. Today 10, 1535\u20131542 (2005).","journal-title":"Drug Discov. Today"},{"key":"BFnbt1342_CR32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0031-6997(24)01349-8","volume":"50","author":"SC Makrides","year":"1998","unstructured":"Makrides, S.C. Therapeutic inhibition of the complement system. Pharmacol. Rev. 50, 59\u201387 (1998).","journal-title":"Pharmacol. Rev."},{"key":"BFnbt1342_CR33","doi-asserted-by":"publisher","DOI":"10.1385\/1592590179","volume-title":"Therapeutic Interventions in the Complement System","author":"JD Lambris","year":"2000","unstructured":"Lambris, J.D. & Holers, V.M. (eds.) Therapeutic Interventions in the Complement System (Humana Press, Totowa, NJ, USA, 2000)."},{"key":"BFnbt1342_CR34","first-page":"1164","volume":"5","author":"MC Holland","year":"2004","unstructured":"Holland, M.C., Morikis, D. & Lambris, J.D. Synthetic small-molecule complement inhibitors. Curr. Opin. Investig. Drugs 5, 1164\u20131173 (2004).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnbt1342_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrd1343","volume":"3","author":"MR Arkin","year":"2004","unstructured":"Arkin, M.R. & Wells, J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3, 301\u2013317 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnbt1342_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1042\/bst0320021","volume":"32","author":"RB Sim","year":"2004","unstructured":"Sim, R.B. & Tsiftsoglou, S.A. Proteases of the complement system. Biochem. Soc. Trans. 32, 21\u201327 (2004).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnbt1342_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1385\/1-59259-017-9:57","volume-title":"Therapeutic Interventions in the Complement System","author":"SV Narayana","year":"2000","unstructured":"Narayana, S.V., Babu, Y.S. & Volanakis, J.E. Inhibition of complement serine proteases as a therapeutic strategy. in Therapeutic Interventions in the Complement System. (eds. J.D. Lambris & V.M. Holers) 57\u201374 (Humana Press, Totowa, New Jersey, 2000)."},{"key":"BFnbt1342_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.4049\/jimmunol.164.1.463","volume":"164","author":"AJ Szalai","year":"2000","unstructured":"Szalai, A.J. et al. The Arthus reaction in rodents: species-specific requirement of complement. J. Immunol. 164, 463\u2013468 (2000).","journal-title":"J. Immunol."},{"key":"BFnbt1342_CR39","doi-asserted-by":"publisher","first-page":"5375","DOI":"10.4049\/jimmunol.167.9.5375","volume":"167","author":"M Buerke","year":"2001","unstructured":"Buerke, M., Schwertz, H., Seitz, W., Meyer, J. & Darius, H. Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits. J. Immunol. 167, 5375\u20135380 (2001).","journal-title":"J. Immunol."},{"key":"BFnbt1342_CR40","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1056\/NEJM198008283030919","volume":"303","author":"A Agostoni","year":"1980","unstructured":"Agostoni, A., Cicardi, M., Bergamaschini, L., Boccassini, G. & Tucci, A. C1-inhibitor concentrate for treatment of hereditary angioedema. N. Engl. J. Med. 303, 527 (1980).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt1342_CR41","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1517\/14656566.2.7.1073","volume":"2","author":"M Kirschfink","year":"2001","unstructured":"Kirschfink, M. & Mollnes, T.E. C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin. Pharmacother. 2, 1073\u20131083 (2001).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFnbt1342_CR42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.transci.2003.08.006","volume":"29","author":"J De Serres","year":"2003","unstructured":"De Serres, J., Groner, A. & Lindner, J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus. Apher. Sci. 29, 247\u2013254 (2003).","journal-title":"Transfus. Apher. Sci."},{"key":"BFnbt1342_CR43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2249.2006.03256.x","volume":"147","author":"HJ Longhurst","year":"2007","unstructured":"Longhurst, H.J., Carr, S. & Khair, K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin. Exp. Immunol. 147, 11\u201317 (2007).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnbt1342_CR44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(00)02483-1","volume":"356","author":"K Bork","year":"2000","unstructured":"Bork, K., Barnstedt, S.E., Koch, P. & Traupe, H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356, 213\u2013217 (2000).","journal-title":"Lancet"},{"key":"BFnbt1342_CR45","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/S0021-9258(19)63283-7","volume":"236","author":"J Pensky","year":"1961","unstructured":"Pensky, J., Levy, L.R. & Lepow, I.H. Partial purification of a serum inhibitor of C\u20321-esterase. J. Biol. Chem. 236, 1674\u20131679 (1961).","journal-title":"J. Biol. Chem."},{"key":"BFnbt1342_CR46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0031-6997(24)01437-6","volume":"52","author":"C Caliezi","year":"2000","unstructured":"Caliezi, C. et al. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev. 52, 91\u2013112 (2000).","journal-title":"Pharmacol. Rev."},{"key":"BFnbt1342_CR47","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.molimm.2006.10.003","volume":"44","author":"EW Nielsen","year":"2007","unstructured":"Nielsen, E.W. et al. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. Mol. Immunol. 44, 1819\u20131826 (2007).","journal-title":"Mol. Immunol."},{"key":"BFnbt1342_CR48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/01.shk.0000235093.83915.0b","volume":"27","author":"M Lauterbach","year":"2007","unstructured":"Lauterbach, M. et al. C1-esterase inhibitor reverses functional consequences of superior mesenteric artery ischemia\/reperfusion by limiting reperfusion injury and restoring microcirculatory perfusion. Shock 27, 75\u201383 (2007).","journal-title":"Shock"},{"key":"BFnbt1342_CR49","unstructured":"Lev Pharmaceuticals. Lev Pharmaceuticals reports positive results in pivotal phase III trial for hereditary angioedema (Lev Pharmaceuticals, New York) (http:\/\/www.levpharma.com\/investors.news.3.14.07.aspx) (March 14, 2007)."},{"key":"BFnbt1342_CR50","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.iac.2006.09.007","volume":"26","author":"BL Zuraw","year":"2006","unstructured":"Zuraw, B.L. Novel therapies for hereditary angioedema. Immunol. Allergy Clin. North Am. 26, 691\u2013708 (2006).","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"BFnbt1342_CR51","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jaci.2005.05.019","volume":"116","author":"MB van Doorn","year":"2005","unstructured":"van Doorn, M.B. et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J. Allergy Clin. Immunol. 116, 876\u2013883 (2005).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnbt1342_CR52","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1196\/annals.1352.033","volume":"1056","author":"E Brook","year":"2005","unstructured":"Brook, E., Herbert, A.P., Jenkins, H.T., Soares, D.C. & Barlow, P.N. Opportunities for new therapies based on the natural regulators of complement activation. Ann. NY Acad. Sci. 1056, 176\u2013188 (2005).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnbt1342_CR53","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1126\/science.2371562","volume":"249","author":"HF Weisman","year":"1990","unstructured":"Weisman, H.F. et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249, 146\u2013151 (1990).","journal-title":"Science"},{"key":"BFnbt1342_CR54","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1586\/14779072.4.5.649","volume":"4","author":"JS Li","year":"2006","unstructured":"Li, J.S., Jaggers, J. & Anderson, P.A. The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev. Cardiovasc. Ther. 4, 649\u2013654 (2006).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"BFnbt1342_CR55","unstructured":"Avant Immunotherapeutics, Inc. Press Release: AVANT Restructures Organization to Focus Resources on Core Programs and Operations (Avant Immunotherapeutics, Needham, MA) http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=93243&p=irol-newsArticle&t=Regular&id=985098& (April 16, 2007)."},{"key":"BFnbt1342_CR56","doi-asserted-by":"publisher","first-page":"11237","DOI":"10.1074\/jbc.274.16.11237","volume":"274","author":"CW Rittershaus","year":"1999","unstructured":"Rittershaus, C.W. et al. Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. J. Biol. Chem. 274, 11237\u201311244 (1999).","journal-title":"J. Biol. Chem."},{"key":"BFnbt1342_CR57","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1042\/bst0301037","volume":"30","author":"RA Smith","year":"2002","unstructured":"Smith, R.A. Targeting anticomplement agents. Biochem. Soc. Trans. 30, 1037\u20131041 (2002).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnbt1342_CR58","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1182\/blood-2005-02-0782","volume":"107","author":"A Hill","year":"2006","unstructured":"Hill, A. et al. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood 107, 2131\u20132137 (2006).","journal-title":"Blood"},{"key":"BFnbt1342_CR59","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jaci.2005.08.003","volume":"116","author":"LG Presta","year":"2005","unstructured":"Presta, L.G. Selection, design, and engineering of therapeutic antibodies. J. Allergy Clin. Immunol. 116, 731\u2013736 (2005).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnbt1342_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0890-8508(87)90022-3","volume":"1","author":"Y Frei","year":"1987","unstructured":"Frei, Y., Lambris, J.D. & Stockinger, B. Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol. Cell. Probes 1, 141\u2013149 (1987).","journal-title":"Mol. Cell. Probes"},{"key":"BFnbt1342_CR61","doi-asserted-by":"publisher","first-page":"8955","DOI":"10.1073\/pnas.92.19.8955","volume":"92","author":"Y Wang","year":"1995","unstructured":"Wang, Y., Rollins, S.A., Madri, J.A. & Matis, L.A. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA 92, 8955\u20138959 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt1342_CR62","unstructured":"Alexion Pharmaceuticals, Inc., FDA approves Alexion's Soliris(TM) for all patients with PNH\u2014first therapy approved for this rare and life-threatening blood disease (Alexion, Cheshire, CT) http:\/\/ir.alexionpharm.com\/releasedetail.cfm?ReleaseID=234156 (March 16, 2007)."},{"key":"BFnbt1342_CR63","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","volume":"33","author":"TC Thomas","year":"1996","unstructured":"Thomas, T.C. et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33, 1389\u20131401 (1996).","journal-title":"Mol. Immunol."},{"key":"BFnbt1342_CR64","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1517\/13543776.16.4.445","volume":"16","author":"LM Proctor","year":"2006","unstructured":"Proctor, L.M., Woodruff, T.M. & Taylor, S.M. Recent developments in C5\/C5a inhibitors. Expert Opin. Ther. Pat. 16, 445\u2013458 (2006).","journal-title":"Expert Opin. Ther. Pat."},{"key":"BFnbt1342_CR65","doi-asserted-by":"crossref","unstructured":"Adis International Ltd. Eculizumab. Drugs R D. 8, 61\u201368 (2007).","DOI":"10.2165\/00126839-200708010-00006"},{"key":"BFnbt1342_CR66","first-page":"870","volume":"3","author":"PA Whiss","year":"2002","unstructured":"Whiss, P.A. Pexelizumab Alexion. Curr. Opin. Investig. Drugs 3, 870\u2013877 (2002).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnbt1342_CR67","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.297.17.1881-b","volume":"297","author":"PW Armstrong","year":"2007","unstructured":"Armstrong, P.W. et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. J. Am. Med. Assoc. 297, 43\u201351 (2007).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnbt1342_CR68","first-page":"69","volume":"16","author":"T Morrow","year":"2007","unstructured":"Morrow, T. A promising theory stumbles in clinical trials. Manag. Care 16, 69\u201370 (2007).","journal-title":"Manag. Care"},{"key":"BFnbt1342_CR69","unstructured":"Steve Mitchell. Analysis: Alexion's pexelizumab fails (January 2, 2007) http:\/\/www.upi.com\/Health_Business\/Analysis\/2007\/01\/02\/analysis_alexions_pexelizumab_fails\/6113\/"},{"key":"BFnbt1342_CR70","doi-asserted-by":"publisher","first-page":"8084","DOI":"10.1073\/pnas.0602357103","volume":"103","author":"C Taube","year":"2006","unstructured":"Taube, C. et al. Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc. Natl. Acad. Sci. USA 103, 8084\u20138089 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt1342_CR71","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","volume":"104","author":"JL Teeling","year":"2004","unstructured":"Teeling, J.L. et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104, 1793\u20131800 (2004).","journal-title":"Blood"},{"key":"BFnbt1342_CR72","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","volume":"177","author":"JL Teeling","year":"2006","unstructured":"Teeling, J.L. et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177, 362\u2013371 (2006).","journal-title":"J. Immunol."},{"key":"BFnbt1342_CR73","doi-asserted-by":"crossref","first-page":"884","DOI":"10.4049\/jimmunol.157.2.884","volume":"157","author":"A Sahu","year":"1996","unstructured":"Sahu, A., Kay, B.K. & Lambris, J.D. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 157, 884\u2013891 (1996).","journal-title":"J. Immunol."},{"key":"BFnbt1342_CR74","doi-asserted-by":"publisher","first-page":"29241","DOI":"10.1074\/jbc.M704587200","volume":"282","author":"BJ Janssen","year":"2007","unstructured":"Janssen, B.J., Halff, E.F., Lambris, J.D. & Gros, P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition, J. Biol. Chem. 282, 29241\u201329247 (2007).","journal-title":"J. Biol. Chem."},{"key":"BFnbt1342_CR75","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0161-5890(02)00212-2","volume":"39","author":"A Sahu","year":"2003","unstructured":"Sahu, A., Morikis, D. & Lambris, J.D. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol. Immunol. 39, 557\u2013566 (2003).","journal-title":"Mol. Immunol."},{"key":"BFnbt1342_CR76","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1021\/jm0603419","volume":"49","author":"M Katragadda","year":"2006","unstructured":"Katragadda, M., Magotti, P., Sfyroera, G. & Lambris, J.D. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J. Med. Chem. 49, 4616\u20134622 (2006).","journal-title":"J. Med. Chem."},{"key":"BFnbt1342_CR77","unstructured":"Potentia Pharmaceuticals, Inc., Potentia Pharmaceuticals announces initiation of phase I clinical trials to evaluate its lead compound for age-related macular degeneration (Potentia, Louisville, KY) http:\/\/www.prnewswire.com\/cgi-bin\/stories.pl?ACCT=104&STORY=\/www\/story\/03-20-2007\/0004549227&EDATE= (March 20, 2007)."},{"key":"BFnbt1342_CR78","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0162-3109(99)00020-X","volume":"42","author":"G Biesecker","year":"1999","unstructured":"Biesecker, G., Dihel, L., Enney, K. & Bendele, R.A. Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 42, 219\u2013230 (1999).","journal-title":"Immunopharmacology"},{"key":"BFnbt1342_CR79","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrmicro1458","volume":"4","author":"DH Bunka","year":"2006","unstructured":"Bunka, D.H. & Stockley, P.G. Aptamers come of age\u2014at last. Nat. Rev. Microbiol. 4, 588\u2013596 (2006).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFnbt1342_CR80","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1955","volume":"5","author":"EW Ng","year":"2006","unstructured":"Ng, E.W. et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5, 123\u2013132 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnbt1342_CR81","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/sj.bjp.0707332","volume":"152","author":"PN Monk","year":"2007","unstructured":"Monk, P.N., Scola, A.M., Madala, P. & Fairlie, D.P. Function, structure and therapeutic potential of complement C5a receptors. Br. J. Pharmacol., 152, 429\u2013448 (2007).","journal-title":"Br. J. Pharmacol."},{"key":"BFnbt1342_CR82","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nature05559","volume":"446","author":"NJ Chen","year":"2007","unstructured":"Chen, N.J. et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 446, 203\u2013207 (2007).","journal-title":"Nature"},{"key":"BFnbt1342_CR83","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2174\/0929867053363379","volume":"12","author":"M Allegretti","year":"2005","unstructured":"Allegretti, M. et al. Targeting C5a: recent advances in drug discovery. Curr. Med. Chem. 12, 217\u2013236 (2005).","journal-title":"Curr. Med. Chem."},{"key":"BFnbt1342_CR84","first-page":"686","volume":"2","author":"AK Wong","year":"1999","unstructured":"Wong, A.K., Taylor, S.M. & Fairlie, D.P. Development of C5a receptor antagonists. IDrugs 2, 686\u2013693 (1999).","journal-title":"IDrugs"},{"key":"BFnbt1342_CR85","first-page":"529","volume":"8","author":"J Kohl","year":"2006","unstructured":"Kohl, J. Drug evaluation: the C5a receptor antagonist PMX-53. Curr. Opin. Mol. Ther. 8, 529\u2013538 (2006).","journal-title":"Curr. Opin. Mol. Ther."},{"key":"BFnbt1342_CR86","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1124\/mol.65.4.868","volume":"65","author":"DR March","year":"2004","unstructured":"March, D.R. et al. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol. Pharmacol. 65, 868\u2013879 (2004).","journal-title":"Mol. Pharmacol."},{"key":"BFnbt1342_CR87","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1096\/fj.05-5814com","volume":"20","author":"TM Woodruff","year":"2006","unstructured":"Woodruff, T.M. et al. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 20, 1407\u20131417 (2006).","journal-title":"FASEB J."},{"key":"BFnbt1342_CR88","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10875-006-9037-z","volume":"26","author":"KA Petersen","year":"2006","unstructured":"Petersen, K.A. et al. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J. Clin. Immunol. 26, 465\u2013475 (2006).","journal-title":"J. Clin. Immunol."},{"key":"BFnbt1342_CR89","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1016\/j.bmc.2007.03.002","volume":"15","author":"S Bureeva","year":"2007","unstructured":"Bureeva, S. et al. Selective inhibition of the interaction of C1q with immunoglobulins and the classical pathway of complement activation by steroids and triterpenoids sulfates. Bioorg. Med. Chem. 15, 3489\u20133498 (2007).","journal-title":"Bioorg. Med. Chem."},{"key":"BFnbt1342_CR90","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nature04005","volume":"437","author":"BJ Janssen","year":"2005","unstructured":"Janssen, B.J. et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437, 505\u2013511 (2005).","journal-title":"Nature"},{"key":"BFnbt1342_CR91","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nature05172","volume":"444","author":"BJ Janssen","year":"2006","unstructured":"Janssen, B.J., Christodoulidou, A., McCarthy, A., Lambris, J.D. & Gros, P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 444, 213\u2013216 (2006).","journal-title":"Nature"},{"key":"BFnbt1342_CR92","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature05263","volume":"444","author":"C Wiesmann","year":"2006","unstructured":"Wiesmann, C. et al. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 444, 217\u2013220 (2006).","journal-title":"Nature"},{"key":"BFnbt1342_CR93","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1126\/science.280.5367.1277","volume":"280","author":"B Nagar","year":"1998","unstructured":"Nagar, B., Jones, R.G., Diefenbach, R.J., Isenman, D.E. & Rini, J.M. X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. Science 280, 1277\u20131281 (1998).","journal-title":"Science"},{"key":"BFnbt1342_CR94","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nsmb1210","volume":"14","author":"FJ Milder","year":"2007","unstructured":"Milder, F.J. et al. Factor B structure provides insights into activation of the central protease of the complement system. Nat. Struct. Mol. Biol. 14, 224\u2013228 (2007).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFnbt1342_CR95","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1006\/jmbi.1994.1021","volume":"235","author":"SV Narayana","year":"1994","unstructured":"Narayana, S.V. et al. Structure of human factor D. A complement system protein at 2.0 A resolution. J. Mol. Biol. 235, 695\u2013708 (1994).","journal-title":"J. Mol. Biol."},{"key":"BFnbt1342_CR96","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1084\/jem.20070432","volume":"204","author":"KJ Katschke Jr.","year":"2007","unstructured":"Katschke, K.J. Jr. et al. A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J. Exp. Med. 204, 1319\u20131325 (2007).","journal-title":"J. Exp. Med."},{"key":"BFnbt1342_CR97","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cbpa.2006.06.014","volume":"10","author":"TH Keller","year":"2006","unstructured":"Keller, T.H., Pichota, A. & Yin, Z. A practical view of 'druggability'. Curr. Opin. Chem. Biol. 10, 357\u2013361 (2006).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"BFnbt1342_CR98","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3\u201326 (2001).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"BFnbt1342_CR99","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd892","volume":"1","author":"AL Hopkins","year":"2002","unstructured":"Hopkins, A.L. & Groom, C.R. The druggable genome. Nat. Rev. Drug Discov. 1, 727\u2013730 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnbt1342_CR100","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/9783527620982.ch4","volume-title":"Modern Biopharmaceuticals","author":"BE Gould Rothberg","year":"2005","unstructured":"Gould Rothberg, B.E., Pena, C.E.A. & Rothberg, J.M. A systems biology approach to target identification and validation for human chronic disease drug discovery. Modern Biopharmaceuticals, vol. 1 (ed. Kn\u00e4blein, J.) 99\u2013125 (Wiley-VCH Verlag, 2005)."},{"key":"BFnbt1342_CR101","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1377\/hlthaff.25.2.420","volume":"25","author":"CP Adams","year":"2006","unstructured":"Adams, C.P. & Brantner, V.V. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff. (Millwood) 25, 420\u2013428 (2006).","journal-title":"Health Aff. (Millwood)"},{"key":"BFnbt1342_CR102","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/nrd919","volume":"1","author":"ME Haffner","year":"2002","unstructured":"Haffner, M.E., Whitley, J. & Moses, M. Two decades of orphan product development. Nat. Rev. Drug Discov. 1, 821\u2013825 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnbt1342_CR103","unstructured":"Title 21. United States Code (USC) Section 360ee."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nbt1342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nbt1342","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nbt1342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T04:49:48Z","timestamp":1737521388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nbt1342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":103,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["BFnbt1342"],"URL":"https:\/\/doi.org\/10.1038\/nbt1342","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11]]},"assertion":[{"value":"7 November 2007","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.D.L., along with the University of Pennsylvania, has one issued and five pending patents on compstatin. These patents have been licensed for ophthalmic indications to Potentia Pharmaceuticals, Inc. J.D.L. is also a nonequity-holding member of the Scientific Advisory Board of Potentia Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}